Novel propargylamine-based inhibitors of cholinesterases and monoamine oxidases: Synthesis, biological evaluation and docking study
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
34492558
DOI
10.1016/j.bioorg.2021.105301
PII: S0045-2068(21)00678-7
Knihovny.cz E-zdroje
- Klíčová slova
- Acetylcholinesterase, Butyrylcholinesterase, Enzyme inhibition, Molecular docking, Monoamine oxidases, Multitargeting ligands, Propargylamine, Salicylic scaffold,
- MeSH
- antioxidancia chemická syntéza chemie farmakologie MeSH
- butyrylcholinesterasa metabolismus MeSH
- cholinesterasové inhibitory chemická syntéza chemie farmakologie MeSH
- cholinesterasy metabolismus MeSH
- Electrophorus MeSH
- hepatocyty účinky léků metabolismus MeSH
- inhibitory MAO chemická syntéza chemie farmakologie MeSH
- koně MeSH
- krysa rodu Rattus MeSH
- kultivované buňky MeSH
- lidé MeSH
- molekulární struktura MeSH
- monoaminoxidasa metabolismus MeSH
- pargylin analogy a deriváty chemická syntéza chemie farmakologie MeSH
- potkani Wistar MeSH
- propylaminy chemická syntéza chemie farmakologie MeSH
- reaktivní formy kyslíku metabolismus MeSH
- simulace molekulového dockingu * MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- vztahy mezi strukturou a aktivitou MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- lidé MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antioxidancia MeSH
- butyrylcholinesterasa MeSH
- cholinesterasové inhibitory MeSH
- cholinesterasy MeSH
- inhibitory MAO MeSH
- monoaminoxidasa MeSH
- pargylin MeSH
- propargylamine MeSH Prohlížeč
- propylaminy MeSH
- reaktivní formy kyslíku MeSH
A combination of several pharmacophores in one molecule has been successfully used for multi-target-directed ligands (MTDL) design. New propargylamine substituted derivatives combined with salicylic and cinnamic scaffolds were designed and synthesized as potential cholinesterases and monoamine oxidases (MAOs) inhibitors. They were evaluated invitro for inhibition of acetyl- (AChE) and butyrylcholinesterase (BuChE) using Ellman's method. All the compounds act as dual inhibitors. Most of the derivatives are stronger inhibitors of AChE, the best activity showed 5-bromo-N-(prop-2-yn-1-yl)salicylamide 1e (IC50 = 8.05 µM). Carbamates (4-bromo-2-[(prop-2-yn-1-yl)carbamoyl]phenyl ethyl(methyl)carbamate 2d and 2,4-dibromo-6-[(prop-2-yn-1-yl)carbamoyl]phenyl ethyl(methyl)carbamate 2e were selective and the most active for BuChE (25.10 and 26.09 µM). 4-Bromo-2-[(prop-2-yn-1-ylimino)methyl]phenol 4a was the most potent inhibitor of MAOs (IC50 of 3.95 and ≈10 µM for MAO-B and MAO-A, respectively) along with a balanced inhibition of both cholinesterases being a real MTDL. The mechanism of action was proposed, and binding modes of the hits were studied by molecular docking on human enzymes. Some of the derivatives also exhibited antioxidant properties. Insilico prediction of physicochemical parameters affirm that the molecules would be active after oral administration and able to reach brain tissue.
Citace poskytuje Crossref.org
